Dr. Ido Hartoghson joins the show to talk about the ideas in his new book, American Trip: Set, Setting, and the Psychedelic Experience in the Twentieth Century  Acknowledging psychedelics as non-specific amplifiers of consciousness, we discuss different historical (and present) paradigms of use in order to interrogate the role of psychedelics within our culture. As we find ourselves staring down a number of existential questions, we must ask ourselves, "What do we hope to achieve through our personal and cultural exposure to psychedelics?”

Recorded live (online) at the Capital Psychedelic Summit in Washington D.C., the Plus Three crew picks up the threads of a recent panel discussion about the effects of corporations and capitalism on the emerging psychedelic landscape. Examining the logic of capitalism, the realities of medicalization, and the need for radical social transformations, we explore philosophies underlying the "Grow, Gather, Give" model, which the Capital Psychedelic Summit organizers explicitly centered for this event.

Recorded live at the Capital Psychedelic Summit, hosted virtually in Washington D.C., Russell Hausfeld joins Brian Normand and David Nickles to discuss the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry. This episode explores the destructive nature of extractive industry and the effects of introducing those dynamics into psychedelia. If the same people destroying Indigenous lands told you they believed in "sacred reciprocity," would you believe them?

In this episode we explore the myriad of problems that result from media outlets treating corporate press releases as though they're legitimate news sources, rather than advertisements. We examine "science by press release" cases ranging from psychedelic pharmaceutical firms who claim their barely-studied compounds are superior to (and safer than) psilocybin (one of the safest psychoactive compounds in the human pharmacopoeia), to students who claimed Oreos were as addictive as cocaine, to pineal DMT, cold fusion, and more.

This episode explores the rise of self-styled “thought leaders” within the psychedelic community, using Anand Giridharadas’ book “Winners Take All” as a jumping off point. Although people have been on the conference circuit for years, the recent explosion of capital investments means that there’s an unprecedented potential for money, celebrity, and status in the space.

In this episode, we discuss a prominent participant in the bumbling coup attempt of January 6: "QAnon Shaman" Jake Angeli. Along with a coalition of Donald Trump supporters and assorted right wing ideologues, Angeli stormed the Capitol following a speech by Trump. Featuring a dissection of an "Ascension Masterclass" that was hosted on Angeli's now-deleted Star Seed Academy Facebook page, we (once again) wade into the disturbing world of psychedelic authoritarianism.

In this episode, we're joined by our new advisory board member Yarelix Estrada to discuss her experiences with organizing psychedelic societies, psychedelic exceptionalism, and harm reduction on the streets of New York. Yarelix shares insights from her formal and practical training in public health as well as her interactions with frontline communities and her personal experiences.

In this episode we sit down with journalist Ioan Grillo to discuss his newest book, Blood Gun Money, which is a look at how the illegal gun and drug trades are intertwined, and how U.S. gun laws result in firearms making their way into black market in Mexico and Latin America, including into the hands of drug cartels.

In this episode we sit down with journalist Ioan Grillo to discuss his newest book, Blood Gun Money, which is a look at how the illegal gun and drug trades are intertwined, and how U.S. gun laws result in firearms making their way into black market in Mexico and Latin America, including into the hands of drug cartels.

Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences' recent IPO on Nasdaq. They also discuss and provide updates on Russell's previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits.